Australia's largest stock trading and investment forum Australia's #1 stock forum

RAP

Click for more information

0.00%

20.5¢ raptor resources limited

Good points. The promising results from the Australian studies...

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 36 Last

Share
Profile

Follow
nequalsone

341 Posts.

911

21/12/17

21:53

Post #: 29816123
Share

Originally posted by investorgadget ↑

Thanks for the clarification. From my understanding leave-one-out cross validation both trains the algorithm and tests it at the same time. This method calculates the "apparent error", or how we expect it to be in real world. But of course your right, what the FDA/TGA/CE want is the "true error"- which is calculated by double blinding. When sample sizes are small, the apparent error could be quite different to the true error - which is what concerns FDA etc and you are probably right as to say they are not clinically valid tests. However with sample sizes as large as the Australian data, the apparent error should very closely reflect the true error and in fact this particular type of testing is slightly pessimistic - meaning the true error is going to be better (given its a large enough sample).

Happy to hear other opinions on this.

Expand

Good points. The promising results from the Australian studies were achieved on 611 subjects (adult study) and 1,127 subjects (Pediatric study). Bodes well for the clinical trial if your theory about apparent and true error holds.

RAP Price at posting: 7.9¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

BUX

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

There are more pages in this discussion • 3 more messages in this thread...

First 36 Last

Add RAP (ASX) to my watchlist